TerminatedPHASE1, PHASE2NCT04409145
First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
Studying Mucocutaneous venous malformations
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Venthera, Inc., a BridgeBio company
- Principal Investigator
- Michael HendersonVenthera, Inc., a BridgeBio company
- Intervention
- VT30(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2020 – 2022
Study locations (15)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital/UAMS, Little Rock, Arkansas, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Dermatology Cosmetic Laser Medical Associates of La Jolla, San Diego, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Indiana University Health (Riley Children's Hospital and University Hospital), Indianapolis, Indiana, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Duke University, Raleigh, North Carolina, United States
- Cincinnatti Children's Hospital, Cincinnati, Ohio, United States
- University Hospitals- Cleveland Medical Center, Cleveland, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
- University of Virginia Department of Dermatology, Charlottesville, Virginia, United States
- University of Wisconsin-Madison, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04409145 on ClinicalTrials.gov